Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.
In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620. © 2026 Published by Elsevier Inc. on behalf of Obesity Medicine Association.
In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620. © 2026 Published by Elsevier Inc. on behalf of Obesity Medicine Association.
What the study was
- Study design
- Randomized controlled trial
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Obesity pillars
Why it surfaced
⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; Design: Randomized controlled trial; species: human
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.